Core Viewpoint - The company has nominated Ms. Wang Zhiyao as an independent non-executive director candidate, pending approval at the upcoming shareholders' meeting [1] Group 1: Board Meeting and Nomination - The company's board of directors will hold its 28th meeting of the 11th session on November 10, 2025, to review the nomination of Ms. Wang Zhiyao [1] - The nomination requires approval from the company's shareholders and will be effective from the date of approval until the end of the 11th board session [1] Group 2: Training and Qualifications - As of the date of the notice for the first extraordinary shareholders' meeting in 2025, Ms. Wang has not yet obtained the independent director training certification [1] - Ms. Wang has committed to participate in the most recent independent director pre-appointment training and has obtained the necessary certification recognized by the Shenzhen Stock Exchange [1] - The qualifications and independence of the independent director candidate have been reviewed and approved by the Shenzhen Stock Exchange without any objections [1]
丽珠医药(01513)：独立董事候选人王智瑶取得深圳证券交易所独立董事培训证明